The Latest Cardiac and Vascular News
-No serious adverse events related to drug product were reported -Patients demonstrated improvements in exercise capacity and reductions in episodes of chest pain -Cardiac imaging results provide mechanistic evidence supporting the therapeutic potential of XC001 in cardiovascular disease WAYNE, Pa.–(BUSINESS […]
– Elizabeth Tarka, M.D. appointed Chief Medical Officer – A. Brian Davis named Chief Financial Officer WAYNE, Pa.–(BUSINESS WIRE)–XyloCor Therapeutics, a clinical‑stage biopharmaceutical company developing novel gene therapies for cardiovascular disease, today announced that it has appointed Elizabeth Tarka, M.D. […]
Company closes additional $22.6 million in new financing Proceeds will fund initiation of new clinical trial for lead gene therapy candidate XC001 as adjunctive therapy for patients undergoing coronary artery bypass graft surgery MALVERN, Pa.–(BUSINESS WIRE)–XyloCor Therapeutics, a private clinical-stage […]
– Novel gene therapy designed to stimulate formation of new coronary blood vessels is being studied in patients with treatment-resistant angina with no remaining treatment options – July 21, 2020 07:00 AM Eastern Daylight Time MALVERN, Pa.–(BUSINESS WIRE)–XyloCor Therapeutics today […]
PHILADELPHIA–(BUSINESS WIRE)–XyloCor Therapeutics, a private clinical‑stage biopharmaceutical company focused on the development of gene therapy for unmet needs in cardiovascular disease, strengthens its leadership team with the appointment of Alexander Gaidamaka, PhD, as Senior Vice President of Technology, Manufacturing & […]
PHILADELPHIA–(BUSINESS WIRE)–XyloCor Therapeutics, a private clinical-stage biopharmaceutical company focused on the development of gene therapy for unmet needs in cardiovascular disease, strengthens its leadership team with the appointment of Rickey Reinhardt, MD, PhD, as Chief Medical Officer. Dr. Reinhardt formerly […]
PHILADELPHIA–(BUSINESS WIRE)–XyloCor Therapeutics, a private clinical-stage biopharmaceutical company focused on the development of gene therapy for unmet needs in cardiovascular disease, today announced the close of a $17 million Series A financing which was co-led by Sofinnova Ventures and LSP […]
